Cancer feature: cnaPANCAN384

ABHD13 ADPRHL1 ANKRD10 ARGLU1 ARHGEF7 ATP11A ATP4B BIVM BIVM-ERCC5 C13orf35 CARKD CARS2 CLYBL COL4A1 COL4A2 CUL4A DAOA DCUN1D2 DOCK9 EFNB2 ERCC5 F10 F7 FAM155A FARP1 FGF14 GAS6 GGACT GPR18 GPR183 GRK1 GRTP1 ING1 IPO5 IRS2 ITGBL1 KDELC1 LAMP1 LIG4 MBNL2 MCF2L METTL21C MYO16 NALCN PCCA PCID2 PROZ RAB20 RAP2A RASA3 RNF113B RP11-65D24.2 SLC10A2 SLC15A1 SOX1 SPACA7 STK24 TEX29 TEX30 TFDP1 TM9SF2 TMCO3 TMEM255B TMTC4 TNFSF13B TPP2 TUBGCP3 UBAC2 ZIC2 ZIC5

Known Driver Genes: ERCC5

Copy number alternation: gain

Podophyllotoxin bromide

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer